Risk for specific hematologic cancers down with GLP-1 receptor agonist use in type 2 diabetes

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a research letter published online March 6 in JAMA Network Open.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup